JSAG Schouten, EC La Heij, CAB Webers, IJ … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Abstract Aim To provide evidence for the effect of bevacizumab on visual acuity
(VA) and central retinal thickness (CRT) in exudative age-related macular
degeneration Methods A systematic review of all articles of bevacizumab for ... Cited by 17 - Related articles - All 2 versions
- ►sagepub.com CR Dass, TMN Tran, PFM Choong - Journal of dental research, 2007 - jdr.sagepub.com Angiogenesis is the formation of new blood vessels from pre-existing vessels to
form capillary networks, which, among other diseases, such as diabetic
retinopathy and macular degeneration, is particularly important for tumor ... Cited by 16 - Related articles - BL Direct - All 2 versions
- ►prsjournal.com TYY Lai, WM Chan, DTL Liu, FOJ Luk, DSC … - British Medical Journal, 2008 - bjo.bmj.com Results: The mean follow-up duration was 12.8 months. At 3 months, the mean
logMAR BCVA improved from 0.61 to 0.51 (p = 0.014), and the mean CFT reduced
from 347 μm to 247 μm (p = 0.015). Despite the visual and anatomical ... Cited by 5 - Related articles - BL Direct - All 5 versions
N Hussain, Y Ghanekar, I Kaur - Indian Journal of Ophthalmology, 2007 - pubmedcentral.nih.gov In the last few years anti-vascular endothelial growth factor (VEGF) therapy has
changed the paradigm in the treatment of neovascular age-related macular
degeneration (ARMD). Besides, its potential use in the treatment of ... Cited by 3 - Related articles - BL Direct - All 4 versions
GK Dy, AA Adjei - CA A Cancer Journal for Clinicians - interscience.wiley.com The 1940s marked the beginning of an era of important discoveries that
contributed to modern concepts underlying the current practice of cancer
chemotherapy, such as the log kill hypothesis reported by Skipper, the ... Cited by 3 - Related articles - All 3 versions
- ►prsjournal.com A Lommatzsch - British Journal of Ophthalmology, 2008 - bjo.bmj.com Intravitreal injection of antibody against vascular endothelial growth factor
(VEGF) to treat CNV, particularly for exudative age-related macular degeneration
(AMD) and CNV associated with pathological myopia, has produced positive ... Cited by 2 - Related articles - BL Direct - All 4 versions
MS Spitzer, F Ziemssen, KU Bartz-Schmidt, F …, 2008 - pubmedcentral.nih.gov Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms
of VEGF-A, significantly slows down loss of vision and causes significant visual
improvement in many patients with choroidal neovascularization (CNV) due to ... Cited by 2 - Related articles - All 6 versions
DB Rein, JS Wittenborn, X Zhang, AA … - Archives of Ophthalmology, 2009 - archopht.highwire.org Methods We simulated cases of early AMD, choroidal neovascularization (CNV),
geographic atrophy (GA), and AMD-attributable visual impairment and blindness
with 5 universal treatment scenarios: (1) no treatment; (2) focal laser and ... Cited by 2 - Related articles - All 2 versions
- ►duanessolution.com R Trevino - Ophthalmic & Physiological Optics, 2008 - duanessolution.com Background: Patients that are deemed to be at risk for the development of
choroidal neovascularization are frequently instructed to self-monitor their
vision for symptoms that may signal the presence of choroidal ... Cited by 2 - Related articles - Cached - BL Direct - All 6 versions
DN Papadopoulou, E Mendrinos, G Mangioris, … - Ophthalmology, 2009 - Elsevier To study the effect of intravitreal (IVT) ranibizumab (Lucentis; Genentech, Inc,
San Francisco, CA) on the retinal arteriolar diameter in patients with
neovascular age-related macular degeneration (AMD). Cited by 1 - Related articles - All 15 versions
